Engineering, production, and biochemical characterization of a human CTLA-4 and IL-10 bispecific fusion protein
Frontiers in Bioengineering and Biotechnology · 20.11.2026 · 14
DOI: 10.3389/fbioe.2026.1964032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 20.11.2026. Verfasst von Adi Cohen und 11 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Bispecific fusion proteins represent a promising strategy for managing complex inflammatory diseases by potential simultaneous binding and modulation of multiple immune pathways. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and interleukin-10 (IL-10) are potent immune suppressors that interact with CD80/86 and IL-10R, respectively. While Fc-fused CTLA-4 is clinically approved, the therapeutic development of IL-10 has been hampered by unpredictable immunostimulatory side effects. Fusing these domains offers a potential approach to leverage their combined immunomodulatory capacities. Herein, we biochemically characterized the binding of the engineered fusion protein to its cognate receptors.
Methods
A fusion protein linking the extracellular domain of CTLA-4 to a fused IL-10 domain was engineered. The protein was expressed in Escherichia coli as an N-terminal GST-tagged variant refolded from inclusion bodies, and as a soluble Fc-tagged variant in mammalian CHO cells. Target specificity and apparent binding affinities were evaluated using ELISA and biolayer interferometry (BLI).
Results
The bacterial and mammalian expression yielded approximately 10 mg/L and 39 mg/L of purified fusion protein, respectively. Both variants successfully demonstrated specific binding to their cognate receptors. Octet BLI analysis of the bacterial protein yielded apparent equilibrium dissociation constants K D of 173.3 nM for CD80 and 45.7 nM for IL-10R. The multivalent mammalian fusion protein bound CD80 with an apparent KD of 462.8 nM, compared to 11.59 nM for the clinical benchmark abatacept, and exhibited exceptionally tight binding to IL-10R (below detection limit <1 pM). Sandwich ELISA confirmed that the mammalian fusion protein can engage both CD80 and IL-10R simultaneously. Finally, in a human virus-specific T cell (VST) co-culture model, the fusion protein successfully inhibited T-cell activation, significantly reducing Interferon-γ (IFNγ) secretion levels.
Conclusion
These findings demonstrate the biochemical feasibility of engineering a bispecific fusion protein composed of CTLA-4 and IL-10 that retains receptor-binding capacity. While this study serves strictly as an initial proof of concept and does not yet demonstrate a synergistic advantage of the covalent linkage, this modular architecture provides a structural basis for future comparative studies and the development of targeted immunomodulators for autoimmune and inflammatory diseases.
Zitieren
APA
Cohen, A., Gabay, M., Cohen, O., Sova, M., Lieberman, A., Shemer, A., Varda-Bloom, N., Jacoby, E., Cafri, G., Avni, D., Yadid, I., & Gal, M. (2026). Engineering, production, and biochemical characterization of a human CTLA-4 and IL-10 bispecific fusion protein. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1964032
Vancouver
Cohen A, Gabay M, Cohen O, Sova M, Lieberman A, Shemer A, et al. Engineering, production, and biochemical characterization of a human CTLA-4 and IL-10 bispecific fusion protein. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1964032
BibTeX
@article{Cohen2026,
author = {Cohen, Adi and Gabay, Matan and Cohen, Omri and Sova, Marina and Lieberman, Amihai and Shemer, Anat and Varda-Bloom, Nira and Jacoby, Elad and Cafri, Gal and Avni, Dorit and Yadid, Itamar and Gal, Maayan},
title = {Engineering, production, and biochemical characterization of a human CTLA-4 and IL-10 bispecific fusion protein},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
volume = {14},
doi = {10.3389/fbioe.2026.1964032}
}
EUVIMED